{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:12Z","timestamp":1792528272561,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 242 patients with RA who were treated with tofacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      = 161) or baricitinib (\n                      <jats:italic>n<\/jats:italic>\n                      = 81) were enrolled. We evaluated efficacy and safety between tofacitinib and baricitinib using multivariable analyses to avoid confounding. Their clinical disease activity and AEs were evaluated for 24\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean (SD) DAS28-ESR change from baseline to 24\u2009weeks was 1.57 (1.55) (tofacitinib) and 1.46 (1.36) (baricitinib). There was no significant difference in the clinical response between the two groups (adjusted mean difference, 0.04; 95% CI, \u22120.35 to 0.28). The efficacy was not significantly changed in the patients without concomitant MTX use in both groups, but the concomitant MTX use showed better clinical efficacy in the cases of baricitinib treatment. In both groups, the most common AE was herpes zoster infection, and the AE rates were similar between the two groups. However, the predictive factors contributing to clinical response as revealed by a multivariable logistic analysis differed. The concomitant oral steroid use was independently associated with the achievement of DAS-low disease activity in the tofacitinib group, whereas in the baricitinib group, the number of biological and\/or targeted synthetic DMARDs previously used was associated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that tofacitinib and baricitinib had comparable continuing efficacies and safety profiles. However, there is a possibility that the influence of clinical characteristics on the treatment response differs. The comparison provides useful information to the optimal use of JAK inhibitors in real-world settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02582-z","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T02:03:04Z","timestamp":1627005784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0757","authenticated-orcid":false,"given":"Naoki","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kurushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Michitsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nishihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshika","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitomo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Origuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"issue":"13","key":"2582_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","journal-title":"JAMA"},{"issue":"6","key":"2582_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2174\/138920101506140910150612","volume":"15","author":"D Wang","year":"2014","unstructured":"Wang D, Li Y, Liu Y, Shi G. The use of biologic therapies in the treatment of rheumatoid arthritis. Curr Pharm Biotechnol. 2014;15(6):542\u20138. https:\/\/doi.org\/10.2174\/138920101506140910150612.","journal-title":"Curr Pharm Biotechnol"},{"issue":"6","key":"2582_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2582_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"2582_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071.","journal-title":"N Engl J Med"},{"issue":"25","key":"2582_CR6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386. https:\/\/doi.org\/10.1056\/NEJMoa1310476.","journal-title":"N Engl J Med"},{"issue":"4","key":"2582_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253\u201361. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2582_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370. https:\/\/doi.org\/10.1002\/art.37816.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2582_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1112072.","journal-title":"N Engl J Med"},{"issue":"9865","key":"2582_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X.","journal-title":"Lancet"},{"issue":"3","key":"2582_CR11","first-page":"485","volume":"37","author":"R Caporali","year":"2019","unstructured":"Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):485\u201395.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2582_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057","volume":"12","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Tsuji S, Takatani A, Shimizu T, Fukui S, Umeda M, et al. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One. 2017;12(5):e0177057. https:\/\/doi.org\/10.1371\/journal.pone.0177057.","journal-title":"PLoS One"},{"issue":"3","key":"2582_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506\u201317. https:\/\/doi.org\/10.1002\/art.39953.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2582_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1608345.","journal-title":"N Engl J Med"},{"issue":"13","key":"2582_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1507247.","journal-title":"N Engl J Med"},{"issue":"1","key":"2582_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094.","journal-title":"Ann Rheum Dis"},{"key":"2582_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/annrheumdis-2020-eular.2074","volume":"79","author":"PMB Gonzalez-Traves","year":"2020","unstructured":"Gonzalez-Traves PMB, Campigotto F, et al. THU0067 JAK selectivity and the impact on cytokine signaling inhibition at clinical rheumatoid arthritis doses. Ann Rheum Dis. 2020;79:246.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2582_CR18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2582_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136. https:\/\/doi.org\/10.1093\/aje\/kwh090.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2582_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276\u201389. https:\/\/doi.org\/10.1038\/nrrheum.2015.8.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2582_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75(4):709\u201314. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207942.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2582_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/rheumatology\/kex068","volume":"56","author":"S Kubo","year":"2017","unstructured":"Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford). 2017;56(8):1293\u2013301. https:\/\/doi.org\/10.1093\/rheumatology\/kex068.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2582_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000538","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, N\u00fc\u00dflein HG, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3(2):e000538. https:\/\/doi.org\/10.1136\/rmdopen-2017-000538.","journal-title":"RMD Open"},{"key":"2582_CR24","doi-asserted-by":"crossref","unstructured":"Hilliquin P, Barnetche T, Baillet A, et al. Real-world 1-year retention rate of subcutaneous tocilizumab treatment in patients with moderate to severe active rheumatoid arthritis: TANDEM study. Rheumatol Ther. 2021;8(1):95\u2013108.","DOI":"10.1007\/s40744-020-00253-0"},{"issue":"1","key":"2582_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2020;22(1):142. https:\/\/doi.org\/10.1186\/s13075-020-02232-w.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2582_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2582_CR27","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960\u20138. https:\/\/doi.org\/10.1002\/art.40189.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2582_CR28","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"C Mark","year":"2020","unstructured":"Mark C, Genovese JSS, Takeuchi T, Burmester G, Brinker D, Rooney TP, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):e347\u2013e57.","journal-title":"Lancet Rheumatol"},{"key":"2582_CR29","doi-asserted-by":"crossref","unstructured":"Guidelli GM, Viapiana O, Luciano N, et al. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol. 2021;39(4):868\u201373.","DOI":"10.55563\/clinexprheumatol\/pudtpo"},{"key":"2582_CR30","doi-asserted-by":"crossref","unstructured":"Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1):e001131.","DOI":"10.1136\/rmdopen-2019-001131"},{"issue":"4","key":"2582_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41584-020-0392-6","volume":"16","author":"S Onuora","year":"2020","unstructured":"Onuora S. Tofacitinib alleviates pain in RA, PsA and AS. Nat Rev Rheumatol. 2020;16(4):186. https:\/\/doi.org\/10.1038\/s41584-020-0392-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2582_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2020","unstructured":"Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2020;51(1):278\u201384. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.008.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02582-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:05:24Z","timestamp":1672884324000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02582-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02582-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-254055\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Investigation and Ethics Committee at Nagasaki University. Patients gave their informed consent to be subjected to the protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}